Infection route | QTL | LRTmax | Position (cM) | CI (95%) | Increase in survival rate | Resistance origin | P value fixed effect | P value interaction | ||
---|---|---|---|---|---|---|---|---|---|---|
Fixed_R (%) | Fixed_S (%) | Fixed_R | Fixed_S | |||||||
IMMERSION | Omy17Omy3 | 13.97* | 61 | 0–92 | 38 | 7 | AP2 | AP2 | *** | NS |
Omy25aOmy3 | 10.41* | 4 | 0–35 | 10 | 18 | B57 | B57 | *** | NS | |
Type 1 interaction | ||||||||||
INJECTION | aOmy3Omy29 | 15.27** | 89 | 46–105 | 16 | 47 | AP2 | AP2 | *** | *** |
IMMERSION | bOmy2Omy3 | 15.35** | 97 | 63–104 | 4 | 39 | B57 | B57 | *** | *** |
bOmy3Omy21 | 40.73*** | 87 | 82–93 | 20 | 55 | AP2 | AP2 | *** | *** | |
cOmy3Omy2 | 35.66*** | 87 | 81–94 | 17 | 44 | AP2 | AP2 | *** | *** | |
INJECTION | aOmy29.2Omy3 | 14.85* | 23 | 8–49 | 5 | 48 | B57 | AP2 | *** | * |
Omy17Omy25a | 15.85** | 73 | 53–79 | 11 | 53 | AP2 | B57 | *** | *** | |
IMMERSION | Omy7.2Omy21 | 11.48* | 7 | 0–103 | 5 | 31 | AP2 | B57 | *** | *** |
Type 2 interaction | ||||||||||
INJECTION | dOmy25aOmy3 | 25.49*** | 14 | 10–18 | 53 | 16 | B57 | B57 | *** | * |
dOmy3Omy25a | 35.35*** | 89 | 86–92 | 59 | 22 | AP2 | AP2 | *** | *** | |
Omy26Omy29 | 11.75* | 18 | 0–34 | 30 | 26 | AP2 | AP2 | *** | *** | |
INJECTION | Omy17Omy29 | 18.29*** | 74 | 58–92 | 47 | 11 | AP2 | B57 | *** | *** |
IMMERSION | Omy24Omy2 | 12.71* | 4 | 0–19 | 20 | 1 | B57 | AP2 | *** | *** |
Type 3 interaction | ||||||||||
IMMERSION | Omy7.1Omy2 | 16.42** | 61 | 32–87 | 19 | 19 | B57 | AP2 | *** | *** |